GlassScriptPhysician profile
Sami N Arslanlar
NPI 1033235684
$141,776.04
in general payments reported to CMS, 2019-2025
43 companies · $34K in 2025
The $34K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $12K · 2021: $11K · 2022: $12K · 2023: $22K · 2024: $24K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $12K · Travel and Lodging: $5,311 · Education: $48.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,925.00 |
| Food and Beverage | $12,304.74 |
| Travel and Lodging | $5,310.53 |
| Education | $48.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132,294.03 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,904.49 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $771.51 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $627.33 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $604.68 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Merck Sharp & Dohme LLC | $482.42 | 2020-2024 | Dificid, Zerbaxa, Recarbrio |
| Ardelyx, INC. | $454.04 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $439.19 | 2022-2025 | Dupixent |
| Pfizer INC. | $394.14 | 2019-2025 | |
| Lilly USA, LLC | $365.74 | 2024-2025 | Omvoh, Zepbound |
| Celgene Corporation | $358.41 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $269.79 | 2022-2024 | Ocaliva |
| Celltrion USA INC. | $240.75 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $222.50 | 2019-2022 | |
| Madrigal Pharmaceuticals | $217.37 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $192.57 | 2019-2023 | Clenpiq |
| Evoke Pharma, INC. | $188.14 | 2023-2025 | Gimoti |
| Shionogi INC | $157.37 | 2019-2020 | |
| Shield Therapeutics INC | $149.28 | 2024 | |
| Redhill Biopharma INC. | $147.65 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $144.43 | 2019-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $142.64 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $136.45 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $102.68 | 2019-2025 | Sutab |
| Vivus LLC | $88.44 | 2025 | Pancreaze |
| Aimmune Therapeutics, INC. | $86.93 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $64.13 | 2024-2025 | Iqirvo, Bylvay |
| Sandoz INC. | $62.88 | 2023 | Hyrimoz |
| Ucb, INC. | $61.95 | 2019-2020 | |
| Allergan, INC. | $58.82 | 2019 | |
| Nestle Healthcare Nutrition INC. | $58.49 | 2021-2022 | |
| Enterra Medical, INC. | $46.54 | 2025 | |
| Novo Nordisk INC | $38.61 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $35.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $32.54 | 2019 | |
| Endo Pharmaceuticals INC. | $27.04 | 2019 | |
| Medtronic, INC. | $24.11 | 2025 | Pillcam |
| Ethicon US, LLC | $19.14 | 2019 | |
| Perspectum Diagnostics LTD | $18.20 | 2022 | |
| Stryker Corporation | $16.24 | 2025 | Pedi-Pom, Neptune |
| Boston Scientific Corporation | $16.01 | 2025 | Enhance Transcarotid Peripheral Access Kit |
| Micro-Tech Endoscopy USA, INC. | $13.25 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$23,803.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Arslanlar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.